Market revenue in 2020 | USD 155.7 million |
Market revenue in 2028 | USD 386.5 million |
Growth rate | 12% (CAGR from 2020 to 2028) |
Largest segment | Reagent-based |
Fastest growing segment | Reagent-based |
Historical data | 2018 - 2019 |
Base year | 2020 |
Forecast period | 2021 - 2028 |
Quantitative units | Revenue in USD million |
Market segmentation | Reagent-based, Physical Disruption |
Key market players worldwide | Thermo Fisher Scientific Inc, Merck KGaA, Bio-Rad Laboratories Inc, Roche Holding AG ADR, Qiagen NV, Danaher Corp, Miltenyi Biotec, IDEX Corp, BD, Claremont BioSolutions, Parr Instrument Company, Covaris, Cell Signaling Technology, Qsonica |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to cell lysis and disruption market will help companies and investors design strategic landscapes.
Reagent-based was the largest segment with a revenue share of 62.11% in 2020. Horizon Databook has segmented the India cell lysis and disruption market based on reagent-based, physical disruption covering the revenue growth of each sub-segment from 2018 to 2028.
India’s biotechnology industry has gained global attention over the past few years and has the potential to become one of the most preferred destinations for global pharmaceuticals manufacturing outsourcing.
In addition, India is one of the key countries with high demand for biopharmaceuticals, along with growing healthcare infrastructure, support from government, and cheap land & labor costs when compared to developed western countries.
Such factors have thus attracted many global biopharma players to invest in the Indian market to expand their business. The market has witnessed collaborations, partnerships, acquisitions, and other deals pertaining to innovative biomanufacturing, research & development, and clinical trials for biologics.
Horizon Databook provides a detailed overview of country-level data and insights on the India cell lysis and disruption market , including forecasts for subscribers. This country databook contains high-level insights into India cell lysis and disruption market from 2018 to 2028, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account